View printer-friendly version
« Back
February 13, 2007 1:27 p.m.
Teva Reports Fourth Quarter And Full Year 2006 Results Provides 2007 outlook

Jerusalem, Israel,, February 13, 2007 -
*Quarterly Net Sales of $2.3 Billion, up 63%; Annual Net Sales of $8.4 Billion, Up 60%

*U.S. GAAP Quarterly EPS of $0.56; U.S. GAAP Annual EPS of $0.69

*Adjusted Quarterly EPS of $0.53, up 18%; Annual Adjusted EPS of $2.30, up 45%

*Cash Flow from Operations: Quarterly $765 Million; Annual $2,058 Million

Net sales for the fourth quarter of 2006 increased 63% to $2,277 million, compared to $1,401 million in the fourth quarter of 2005. The main contributors to the growth in sales for the quarter were the inclusion of Ivax sales, which benefited all regions, and new products sold in the U.S. that were not sold in the comparable quarter of 2005. Net sales for fiscal 2006 reached $8.4 billion, an increase of 60% over 2005 sales.

On a U.S. GAAP basis, net income for the fourth quarter of 2006 increased 51% to $460 million, compared to $305 million for the same period of 2005, and fully diluted earnings per share increased 24% to $0.56.

Adjusted net income, after eliminating certain tax-related income and certain charges recorded in the fourth quarter of 2006, reached $433 million for the quarter, an increase of 42%, and adjusted fully diluted earnings per share reached $0.53, an increase of 18%. These adjusted data are considered non-GAAP financial measures. Teva believes that excluding these items facilitates investors' understanding of the trends in the Company's underlying business.

For the full year of 2006, on a U.S. GAAP basis, net income and earnings per share reached $546 million and $0.69, a decrease of 49% and 57%, respectively, compared to 2005. Adjusted net income, after eliminating charges relating principally to the acquisition of Ivax, reached $1,867 million, an increase of 74% and adjusted fully diluted earnings per share in 2006, reached $2.30 per share, an increase of 45%, over the full year of 2005.

Except as otherwise noted, the analysis below addresses the adjusted figures.

Israel Makov, President and CEO, said: "Q4 was a very good quarter, ending what was not just another strong year for Teva, but an exceptionally strong one. This was an extraordinary year financially as well as strategically, as we established important additional platforms for growth in our business. Once again we have proven the strength of our strategies, and our excellence in executing those strategies. In 2006, Teva not only enhanced its leadership of the global generics industry, but expanded its role in the fields of CNS and Respiratory. I truly believe that Teva is ideally positioned to play an even larger role in the health care industry, and capture an even larger share of the opportunities that this industry offers."

North America accounted for 59% of Q4 net sales, while Europe contributed 24% and International (primarily Latin America, Central and Eastern Europe and Israel) 17%.

North American pharmaceutical sales (including Copaxone®) reached $1,252 million in the quarter, compared to $776 million in the fourth quarter of 2005, an increase of 61%. Sales benefited this quarter from 18 new products that were not sold in the comparable quarter of 2005, the most significant being the exclusive launch of bupropion XL during the fourth quarter of 2006, as well as of products launched in previous quarters of 2006, such as venlafaxine. In addition, sales benefited from the consolidation of Ivax, including increased sales of respiratory products, as well as higher sales of Copaxone® and the introduction of Azilect® in the U.S and Canada.

As of February 1, 2007, Teva had 162 product applications awaiting final FDA approval. Collectively, the brand products covered by these applications had annual U.S. sales of approximately $92 billion. Teva believes it is the first to file on 42 of these applications relating to products whose annual U.S. branded sales are over $36 billion.

Pharmaceutical sales in Western Europe (including Hungary and Copaxone®) increased 43% in the quarter to $513 million. In addition to the acquisition of Ivax, the increase is due to higher generic sales (including 39 product launches across various markets this quarter) and increased Copaxone® and Azilect® sales.

International pharmaceutical sales (including Copaxone®), which include primarily Latin America, Israel and Central and Eastern European countries, increased 191% in the quarter to $361 million. The increase is due to the addition of new markets in Latin America and Central and Eastern Europe as a result of the Ivax acquisition as well as expanding sales in existing markets.

Global in-market sales of Copaxone®, which continued to expand its global leadership position, reached $378 million, an increase of 17% over the fourth quarter of 2005. U.S. in-market sales increased by 9% to $238 million. In-market sales outside the U.S., mainly in Europe, increased by 35% to $139 million. For the full year of 2006, global in-market sales of Copaxone® increased by 20% to $1,414 million, with U.S. in-market sales increasing by 17% to $916 million and non-U.S. sales increasing by 26% to $498 million, reflecting higher sales in Teva's main Western European markets as well as in Russia and certain Latin American countries.

Azilect®, Teva's second innovative drug, continued its successful entry, making inroads among the existing products for the treatment of Parkinson's disease in the U.S. and Europe, with global sales in the quarter of $19 million and annual sales of $44 million. Azilect® is now available in 24 countries.
API sales to third parties reached a quarterly record of $151 million, an increase of 7% over the fourth quarter of 2005. Total API sales (including internal sales) were $281 million, a decrease of 5% compared to the fourth quarter of 2005. The decrease in internal sales largely reflects higher than normal volumes of raw material sales in the comparable 2005 fourth quarter in preparation for the 2006 vertically integrated large product launches with exclusivity.
Gross profit margin reached 48.4% in the fourth quarter of 2006, which was similar to the gross profit margin of the fourth quarter of 2005. The gross margin this quarter declined from the exceptionally high gross margins of the second and third quarters of 2006, which were attributable to high sales of newly launched products with exclusivity. In addition to the shelf stock adjustments that were made due the anticipated loss of exclusivities on simvastatin, pravastatin and finasteride that occurred during the quarter, the company absorbed nearly $50 million more in shelf-stock adjustments for simvastatin than had been expected, due to the retention of a much larger-than-expected market share of simvastatin following the end of the exclusivity period.

Net Research & Development expenditures grew by 40% over the comparable quarter of 2005 and reached $137 million. R&D as a percentage of sales reached 6%.

Selling, General and Administrative (SG&A), which represented 21% of sales during the quarter, amounted to $478 million, as compared to 15.5% of sales and $217 million in the fourth quarter of 2005. This higher level of SG&A in the reported quarter primarily reflects the substantially higher proportion of branded business mainly as a result of the Ivax acquisition. In addition, higher sales of products in the U.S., in which Teva shares its profit with third parties, and the expensing of employee stock options increased SG&A this quarter.
The Tax Rate provided for the fourth quarter was 12.9% of pre-tax income compared with 12.5% in the previous quarter and 13.7% in the comparable quarter. This adjusts the annual tax rate from 15.5% to 14.9% of adjusted pre-tax income, compared with a rate of 18% for 2005.

Cash flow generated from operating activities during the fourth quarter of 2006 amounted to $765 million, bringing the total operating cash flow for the year to $2,058 million. Free cash flow generated in 2006 net of dividends and capital expenditures amounted to $1,463 million.
Cash and marketable securities amounted to $2.3 billion as of December 31, 2006.

Share repurchases by Teva- during the fourth quarter totaled approximately 7.3 million shares for an aggregate purchase price of $234 million. An additional 3.3 million shares were purchased in 2007 for $112 million. Overall Teva repurchased 10.6 million shares for an amount equal to $346 million reflecting an average price of $32.49 per share.

Shareholders Equity on December 31, 2006 reached $11.1 billion, up by $563 million from September 30, 2006.

Share Count - For the fourth quarter of 2006, the share count for the fully diluted earnings per share calculation was 832 million shares. As of December 31, 2006 and going forward, Teva's share count for the fully diluted share count calculation is estimated at 832 million shares.

2007 Outlook - The Company expects net sales in 2007 to exceed $9 billion and fully diluted earnings per share to be in the range of $2.07 to $2.19.


The Board of Directors, at its meeting on February 12, 2007, declared a cash dividend for the fourth quarter of 2006 of NIS 0.40 (approximately 9.4 cents according to the rate of exchange on February 12, 2007) per share. The record date will be February 21, 2007, and the payment date will be March 8, 2007. Tax will be withheld at a rate of 16%.

Conference Call

Teva will host a conference call to discuss the Company's fourth quarter and year end results on Tuesday, February 13, 2007 at 08:45 a.m. EST. The call will be webcast and can be accessed through the Company's website at Following the conclusion of the call, a replay of the webcast will be available within 24 hours at the Company's web site. Alternatively, a replay of the call will be available until February 21, 2007 at 11:59 (ET), by calling 1-(201) 612-7415 outside the U.S. or 1-(877) 660-6853 in the U.S. The Pass Code to access the replay is: Account #: 3055 and Conference ID#: 229480.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80% of Teva's sales are in North America and Europe.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on managements current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Tevas future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: Teva's ability to accurately predict future market conditions including pricing and margins with regard to sales of the generic version of Protonix®, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra®, Neurontin®, Lotrel® Famvir® and Protonix®, Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, the effects of competition on our innovative products, especially Copaxone® sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Tevas ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Tevas Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.